Cargando…
Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching
Background: Cell and gene therapies are associated with uncertainty around their value claims at launch due to limitations of supporting clinical data; furthermore, their high costs present affordability issues for payers. Outcomes-based reimbursement can reduce payer decision uncertainty and improv...
Autores principales: | Jørgensen, Jesper, Mungapen, Laura, Kefalas, Panos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366432/ https://www.ncbi.nlm.nih.gov/pubmed/30774785 http://dx.doi.org/10.1080/20016689.2019.1573164 |
Ejemplares similares
-
A price comparison of recently launched proprietary pharmaceuticals in the UK and the US
por: Jørgensen, Jesper, et al.
Publicado: (2016) -
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
por: Jørgensen, Jesper, et al.
Publicado: (2020) -
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
por: Kefalas, Panos, et al.
Publicado: (2018) -
Reimbursement of licensed cell and gene therapies across the major European healthcare markets
por: Jørgensen, Jesper, et al.
Publicado: (2015) -
Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
por: Jørgensen, Jesper, et al.
Publicado: (2017)